Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL223345 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL9995855 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL4661565 | 0.92 | — | — | |
| Glycine SCHEMBL10906749 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5943682 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5187484 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL5689090 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL2161269 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3121145 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL142870 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213400-A1 | Combinations of Chromium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080181970-A1 | Combinations of Vanadium with Antidiabetics for Glucose Metabolism Disorders | AKESIS PHARMACEUTICALS (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-20070293566-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070281042-A1 | Combinations of chromium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070207218-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070197425-A1 | Combinations of chromium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070196512-A1 | Combinations of vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070161540-A1 | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders | AKESIS PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20020187204-A1 | Diet composition and method of weight management | ALVIAR BARBARA (US) | 2002-12-12 | — | — | US | disclosed |
| US-6413545-B1 | ADMINISTERING MIXTURE CONTAINING PLANT EXTRACTS; APPETITE SUPPRESSANT | ACCESS BUSINESS GROUP INTERNATIONAL LLC | 2002-07-02 | — | — | US | disclosed |
| EP-1113804-A2 | COMBINATIONS OF CHROMIUM OR VANADIUM WITH ANTIDIABETICS FOR GLUCOSE METABOLISM DISORDERS | Akesis Pharmaceuticals, Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001003700-A1 | COMBINATION OF CHROMIUM AND VANADIUM FOR GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000057721-A2 | EDIBLE SOLIDS FOR TREATMENT OF GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000057729-A2 | BEVERAGES FOR TREATMENT OF GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000015211-A2 | COMPOSITIONS OF CHROMIUM OR VANADIUM WITH ANTIDIABETICS FOR GLUCOSE METABOLISM DISORDERS | AKESIS PHARMACEUTICALS, INC. (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000012080-A1 | DIET COMPOSITION AND METHOD OF WEIGHT MANAGEMENT | AMWAY CORPORATION (US) | 2000-03-09 | — | — | WO | disclosed |
| US-5550113-A | MIXTURE OF INSULIN AND A METAL COMPLEX | MANN MORRIS A (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996002263-A1 | BLOOD SUGAR REGULATING COMPOSITIONS CONTAINING INULIN AND ONE OR MORE METAL COMPLEXES | MANN MORRIS A (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | CA4 2922/4885GLRA1 2621/4885SLC6A9 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.